Hypophosphatasia is a rare inherited metabolic disorder in which the body produces too little of an enzyme called alkaline phosphatase, leading to bones and teeth that don’t mineralize properly. The condition ranges from fatal in its most severe newborn form to a chronic, often misdiagnosed source of fractures and dental problems in adults. First described in 1948 by Dr. John Campbell Rathbun in an infant with rickets and seizures, hypophosphatasia has since been linked to mutations in a single gene, but its effects ripple across the skeleton, the brain, and everyday quality of life in ways that make it far more complex than a “bone disease.”
What Goes Wrong at the Cellular Level
The enzyme at the center of hypophosphatasia is tissue-nonspecific alkaline phosphatase, often shortened to TNSALP. Normally, TNSALP breaks down several substances outside cells, and one of its most important jobs is clearing away a molecule called inorganic pyrophosphate. Pyrophosphate acts like a brake on mineral crystal growth: as long as it hangs around, the calcium-phosphate crystals that make bone hard cannot form properly. In healthy people, TNSALP keeps pyrophosphate levels in check. In people with hypophosphatasia, pyrophosphate accumulates and effectively blocks bones from hardening after the initial crystal seeds are released from specialized structures in bone tissue.1Genetics of Bone Biology and Skeletal Disease. Hypophosphatasia and How Alkaline Phosphatase Promotes Mineralization
TNSALP also normally breaks down pyridoxal 5′-phosphate (PLP), the active circulating form of vitamin B6. When the enzyme isn’t working, PLP accumulates in the blood but paradoxically cannot reach the brain in the form neurons need, because it must be dephosphorylated first to cross the blood-brain barrier. Inside the brain, the unphosphorylated form gets re-converted back to PLP to serve as a helper molecule for making the inhibitory neurotransmitter GABA. Without enough GABA, the brain becomes over-excitable, which explains why severely affected infants can develop seizures that respond to vitamin B6 supplementation.2Journal of Clinical Research in Pediatric Endocrinology. Hypophosphatasia Presenting with Pyridoxine-Responsive Seizures, Hypercalcemia, and Pseudotumor Cerebri: Case Report A third substance, phosphoethanolamine, also builds up, though its clinical effects are less well understood than those of pyrophosphate and PLP.3Archivos Brasileiros de Endocrinologia e Metabologia. Hypophosphatasia: from birth to adulthood
How the Disease Is Inherited
Hypophosphatasia is caused by mutations in the ALPL gene, which provides the instructions for making TNSALP. The inheritance pattern depends on severity. The most severe forms, perinatal and infantile, are typically autosomal recessive, meaning a child must inherit a faulty copy of the gene from each parent. Milder childhood and adult forms can be either recessive or dominant, where a single mutated copy is enough to cause symptoms. This variability makes genetic counseling tricky: a family can carry the same mutation yet have members with wildly different degrees of illness.4Molecular Genetics and Metabolism Reports. Multigenerational case examples of hypophosphatasia: Challenges in genetic counseling and disease management
In a large U.S. cohort of people with suspected hypophosphatasia, roughly 87% of those carrying a single ALPL variant had one classified as clearly disease-causing. Among individuals with two variants, almost all were compound heterozygotes, meaning they carried two different mutations rather than two copies of the same one.5Molecular Genetics and Metabolism. Genetic characterization of a large cohort of individuals with a clinical suspicion of hypophosphatasia in the United States A separate study of 43 individuals found 30 distinct genotypes, underscoring the sheer variety of mutations involved.6Journal of Bone and Mineral Research. Biochemical phenotype of hypophosphatasia in asymptomatic individuals carrying ALPL variants The practical upshot is that even asymptomatic carriers can show biochemical signs of the disease, and two parents who each feel perfectly healthy can have a severely affected child.
The Clinical Spectrum
Hypophosphatasia is often classified by the age when symptoms first appear, but the reality is more of a continuum than a set of neat categories. The perinatal form, recognized at or before birth, is the most severe. Imaging may show poorly ossified or absent bones, shortened and bowed limbs, and thin ribs that compromise breathing. Historical survival rates for infants requiring ventilatory support were grim. In one analysis, only about 5% of ventilated historical-control infants survived, illustrating how lethal untreated perinatal disease once was.7PubMed Central. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
The infantile form appears within the first six months and shares many features with the perinatal form: poor bone mineralization, failure to thrive, and in some cases vitamin B6-responsive seizures.8Bone. Hypophosphatasia: Vitamin B6 status of affected children and adults Childhood-onset hypophosphatasia tends to present with rickets-like bone changes, leg deformities, growth problems, and early loss of baby teeth. Muscle and joint complaints are common in this age group and can actually be more prominent than the bone findings, sometimes steering clinicians toward the wrong diagnosis.9PubMed. Hypophosphatasia in children and adolescents: clinical features and treatment
In adults, hypophosphatasia often masquerades as osteoporosis. Recurrent stress fractures, especially in the feet and femurs, chronic musculoskeletal pain, and stiffness may be the only obvious signs. A study screening patients at a podiatry clinic with metatarsal stress fractures found that among those who had low alkaline phosphatase levels, about 15% turned out to carry a disease-causing ALPL mutation. Those patients reported far higher pain and disability than controls.10PubMed Central. Diagnosis of Hypophosphatasia in Adults Presenting With Metatarsal Stress Fracture: Proof‐of‐Concept for a Case‐Finding Strategy
Teeth as an Early Warning Sign
For many people with hypophosphatasia, the first clue is dental. Children with the condition often lose their baby teeth unusually early, sometimes before age two. The root cause is a defect in cementum, the specialized tissue that anchors a tooth’s root to the surrounding bone via the periodontal ligament. In hypophosphatasia, cementum either fails to form or forms incompletely, meaning the tooth has a weak grip on its socket. Even mild force can loosen and eventually knock it out.11Japanese Dental Science Review. Dental manifestation and management of hypophosphatasia
This is distinct from normal baby-tooth loss. When a healthy child loses a tooth, the root has been naturally resorbed. In hypophosphatasia, the teeth come out intact, root and all, because the attachment was never strong to begin with.12PubMed Central. Dental manifestations of hypophosphatasia: translational and clinical advances This detail is a red flag that pediatric dentists are trained to recognize, but it can still be overlooked. Case reports describe diagnostic delays of a decade or more in which repeated premature tooth loss was not connected to an underlying metabolic disorder.13Frontiers in Oral Health. Decade-long delayed diagnosis of hypophosphatasia until next generation tooth loss: case reports on dental rehabilitation, diagnostic challenges and clinical implications
Why Hypophosphatasia Gets Misdiagnosed
One of the biggest practical problems with hypophosphatasia is that it looks like several other, more common conditions. In children it mimics nutritional rickets. In adults it mimics osteoporosis or osteogenesis imperfecta. And the standard lab test that could point to the right diagnosis, alkaline phosphatase, is routinely ordered but rarely flagged when it comes back low. Clinicians are trained to worry about high alkaline phosphatase; a low reading often goes unnoticed.
This matters enormously because some standard treatments for the conditions hypophosphatasia mimics can make things worse. Bisphosphonates, a mainstay of osteoporosis therapy, work partly by further suppressing bone turnover. In a person whose bone mineralization is already impaired by low alkaline phosphatase activity, adding a bisphosphonate is counterproductive and has been documented to cause atypical femoral fractures. One case report described a woman who developed subtrochanteric fractures after four years on bisphosphonates given for presumed osteoporosis; only after the fractures did clinicians check and find her alkaline phosphatase was low, leading to a belated diagnosis.14Journal of Bone and Mineral Research. “Atypical femoral fractures” during bisphosphonate exposure in adult hypophosphatasia Another case described a 13-year diagnostic delay in which the patient was first misdiagnosed with nutritional rickets, then reclassified as osteogenesis imperfecta, and treated with bisphosphonates that led to atypical fractures.15PubMed Central. Atypical Fracture From Bisphosphonate Use in Hypophosphatasia With Improved Bone Response to Teriparatide Therapy
A useful diagnostic starting point is simply paying attention to alkaline phosphatase when it is low. One study of adults with metabolic bone disease found that a total alkaline phosphatase level at or below 43 IU/L, combined with an elevated PLP level of 120 nmol/L or more, reliably distinguished hypophosphatasia from other bone conditions.16PubMed. Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic Genetic testing then confirms the diagnosis. Clinicians aware of conditions that independently alter alkaline phosphatase, such as liver disease, excess vitamin D, or thyroid disorders, can avoid being misled by borderline values.
Living with Adult Hypophosphatasia
Even when hypophosphatasia is correctly identified, it takes a real toll on daily life. Data from a global registry of adults with the condition paint a picture of chronic pain, limited mobility, and reduced quality of life. On a standard pain-severity scale, median worst pain over the preceding 24 hours was 5 out of 10, and about 30% of patients were taking pain medications, with roughly 12% using opioids.17Journal of Bone and Mineral Research. Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry
Self-reported disability was higher than in the general population, and more than half of patients said their health negatively affected both physical and mental functioning. The physical component scores on a widely used quality-of-life questionnaire averaged well below the general population norm. Patients whose symptoms began in childhood had significantly greater disability than those with adult onset, suggesting that years of undermineralized bone and compensatory movement patterns compound the functional burden over time.18Journal of Bone and Mineral Research. Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry Chronic pain, recurrent fractures, and the orthopedic complications that follow have been described as having a serious negative impact across all aspects of patients’ lives.19PubMed Central. Hypophosphatasia: clinical manifestation and burden of disease in adult patients
Enzyme Replacement Therapy
For decades, treatment was purely supportive: managing fractures with surgery, controlling seizures with vitamin B6, and trying to preserve dental function. That changed with asfotase alfa, an engineered version of the missing enzyme approved for treatment of hypophosphatasia. The drug is designed to home in on bone by carrying a sequence that binds to mineral surfaces, delivering enzyme activity where it’s needed most.
In infants with life-threatening disease, the results have been striking. In a study comparing treated infants against age-matched historical controls, survival at one year was about 95% in the treated group versus 42% in controls, and at five years it was 84% versus 27%. Among infants who required ventilatory support, about three-quarters of those treated survived, and most of those survivors were eventually weaned off ventilation, compared with only 5% survival among ventilated historical controls.20PubMed Central. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia Over longer follow-up, the drug has improved not just survival but also skeletal development, physical and motor function, and quality of life across age groups.21PubMed Central. Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10 Years Post-Approval
In adults, the improvements are more modest but still meaningful. Registry data show that pain scores dropped over three years of treatment, with the largest reductions in worst-pain ratings. Walking distance on a standard six-minute test improved as well, gaining roughly 90 meters at one year.22PubMed Central. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry A separate study in adults with pediatric-onset disease found significant gains in walking speed, chair-rise time, hand grip strength, and physical function scores sustained over two years, though pain levels did not significantly change in that particular cohort.23PubMed. Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 2 months of treatment In at least one case of adult-onset disease, pseudofracture lines visible on X-ray disappeared within six months of starting treatment, along with marked improvement in mobility and resolution of chronic pain.24JBMR Plus. The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult‐Onset Hypophosphatasia
What Enzyme Replacement Does and Doesn’t Fix for Teeth
Because the dental problems in hypophosphatasia stem from the same enzyme deficiency, there was hope that enzyme replacement would prevent premature tooth loss. Early evidence suggests it helps, but with caveats. Children who started treatment as infants lost significantly fewer teeth prematurely than those who began treatment as preschoolers, pointing to a window of opportunity: the earlier the enzyme is available during tooth development, the better the cementum forms.25PubMed. Dental outcomes for children receiving asfotase alfa for hypophosphatasia A scoping review of multiple studies found that enzyme replacement generally reduced the presence and severity of oral problems, but some treated children still lost baby teeth, and many studies did not report detailed dental outcomes.26PubMed. The impact of enzyme replacement therapy on the oral health manifestations of hypophosphatasia among children: a scoping review For now, dental monitoring remains a core part of managing the condition even for patients on treatment.
Orthopedic and Surgical Challenges
Hypophosphatasia can require substantial surgical management, particularly in patients who accumulate deformities or recurrent fractures over years. One case report described a woman who underwent intramedullary nailing of six different long bones over 13 years to address fractures and bowing.27PubMed. Intramedullary nailing for adult hypophosphatasia: a case report In severe infantile cases, craniosynostosis, the premature fusion of skull bones, can occur and may require neurosurgical intervention. Historically, operating on a child with profoundly undermineralized bone carried enormous risk; enzyme replacement therapy has improved bone quality enough to make these surgeries feasible.28Neurosurgical Focus. Enzyme replacement therapy for congenital hypophosphatasia allows for surgical treatment of related complex craniosynostosis: a case series
Joint problems add another layer. The accumulation of pyrophosphate crystals in and around joints can trigger a form of crystal arthropathy similar to what occurs in gout, though driven by a different type of crystal. This joint involvement sometimes appears before the underlying metabolic diagnosis is made, adding another avenue through which hypophosphatasia hides behind a more familiar-sounding label.
Gene Therapy on the Horizon
Enzyme replacement therapy works, but it requires frequent injections, often multiple times per week for life, and it does not cure the underlying genetic defect. Researchers are exploring gene therapy as a potentially longer-lasting approach. In mouse models of hypophosphatasia, a single dose of a viral vector carrying a bone-targeted version of the TNSALP gene prevented seizures, kept the animals alive well past the point where untreated mice typically died, and produced skeletal development that looked grossly normal on X-ray.29Journal of Bone and Mineral Research. Gene Therapy Using Adeno‐Associated Virus Serotype 8 Encoding TNAP‐D10 Improves the Skeletal and Dentoalveolar Phenotypes in Alpl−/− Mice In a follow-up study using a model of milder adult-type disease, the same approach significantly improved cortical bone quality with no detectable adverse effects.30PubMed Central. Gene Therapy Using Recombinant AAV Type 8 Vector Encoding TNAP‐D10 Improves the Skeletal Phenotypes in Murine Models of Osteomalacia
These are animal-model results, and the jump to humans involves major unknowns: how long the gene therapy’s effect lasts, how the immune system responds over years, and whether a single treatment can provide enough enzyme in all the places that need it. But for a disease that was essentially untreatable until about a decade ago, the pace of progress has been remarkable. Even the original case described by Rathbun in 1948 was eventually revisited decades later, and the specific ALPL mutation was identified through molecular analysis of archived tissue, connecting the very first patient to the modern genetic understanding of the disease.31PubMed. Hypophosphatasia: molecular diagnosis of Rathbun’s original case
Imaging Clues That Point to the Diagnosis
Radiologists familiar with hypophosphatasia can sometimes spot it on an X-ray or prenatal ultrasound before blood work is even drawn. In the perinatal form, characteristic features include poorly ossified or absent bones (especially of the skull vault), thin ribs, and an unusual pattern of metaphyseal lucencies at the ends of long bones. Shortening, bowing, and angulation of the limbs may all be present, though not every case shows every feature. Absent ossification of entire bones is fairly specific to the most severe lethal form and narrows the differential diagnosis considerably.32Pediatric Radiology. Differential diagnosis of perinatal hypophosphatasia: radiologic perspectives In adults, the findings are subtler: stress fractures in unusual locations, lateral cortical thickening of the femur that resembles the atypical fractures seen with bisphosphonate use, and sometimes pseudofractures, which are incomplete fracture lines that appear on X-ray without a history of trauma. These imaging patterns, combined with low alkaline phosphatase on blood work, can help a radiologist or orthopedist push toward the right diagnosis before years of misdirected treatment go by.